Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

In 2025, the American Cancer Society estimates that 36,110 new cases of multiple myeloma will be diagnosed, affecting about 20,030 men and 16,080 women. Who gets multiple myeloma?

By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

Multiple myeloma begins when abnormal cells multiply and grow uncontrollably in a person’s bone marrow, crowding out healthy ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

Bone lesions and soft spots that occur because of multiple myeloma are difficult to treat. They may cause continued fractures, even if the cancer itself has gone into remission.

Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all ...

Bone Pain and Fractures Bone pain, typically in the spine or ribs but possibly in any bone, is often one of the earliest signs of multiple myeloma. Myeloma cells stimulate cells that break down ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

Dimitrios Christoulas; Evangelos Terpos; Meletios A Dimopoulos Disclosures Expert Rev Hematol. 2009;2 (4):385-398.